Team

Scientific Founders

The scientific founders of R2 Technologies are renowned for their widely used aesthetic innovations, including fractional photothermolysis (Fraxel ®) and cryolipolysis (CoolSculpting ®)*

R. ROX ANDERSON, M.D.

Director of the Wellman Center of Photomedicine at Massachusetts General Hospital in Boston, a teaching affiliate of Harvard Medical School.

DIETER MANSTEIN, M.D.,PH.D.

The Cutaneous Biology Research Center in the Department of Dermatology at Massachusetts General Hospital.

HENRY H.L. CHAN, M.D., PH.D

Honorary Clinical Professor, Department of Medicine, The University of Hong Kong and the Visiting Scientist of the Wellman Center for Photomedicine, Massachusetts General Hospital.

The R2 Team

TIM HOLT

Chief Executive Officer

Tim has a proven track record of taking companies from start-up to IPO/acquisition. For over 17 years, he has worked in the aesthetic device industry, starting at the early stages of both Reliant and ZELTIQ.

KRISTINE TATSUTANI

Chief Scientific Officer

Kristine has dedicated her 25-year career to cryobiology research and the development of cold-based medical devices. She held a leadership position at ZELTIQ and dedicated the last decade to aesthetic applications for cold therapies.

MICHAEL LAMBERSON

Senior Vice President of Marketing

Mike has 20 years of experience helping healthcare companies bring innovative technologies to market. Mike’s career began at Johnson & Johnson in operations and commercial roles. More recently, he held commercial roles at Biolux Research, Elira, and ZELTIQ.

ROGER SCHMID

Vice President of International Sales

Roger has been in the pharmaceutical/medical device industry for over 20 years. He jumped into aesthetic medicine in 2012 with ZELTIQ, assuming the role as Managing Director of APAC for CoolSculpting. He then moved on to miraDry where he built and managed the APAC, Middle East and LATAM business.

CHRIS MCGREEVY

Vice President of North American Sales

Chris has led high performing sales teams in the aesthetic device industry for 25 years. He started his career with Coherent Medical Lasers and most recently has held Vice President of Sales positions with Biolux Research, MiraDry and ZELTIQ.

RAGAN REPPOND

Senior Director of HR and Corporate Affairs

For the last 20 years, Ragan has worked in the high-tech and medtech industry. She has been instrumental in multiple stages of the IPO process, most recently with ZELTIQ.

KEVIN SPRINGER

Director of Clinical Engineering

For over 28 years, Kevin worked as a pre-clinical and clinical engineer at companies that develop medical devices for anesthesia, obstetrics, urology, and aesthetics, recently with ZELTIQ.

JAMES HASTINGS

Senior Director of Marketing

James has held progressive sales and marketing roles for over 20 years, including roles with aesthetic companies including Laserscope, Iridex, Lumenis, and ZELTIQ.

ANDREW ROIG

Director of Product Marketing & Partnerships

Andrew has led product development, marketing, and education for notable brands within the aesthetics space, including HydraFacial, iS Clinical, Estee Lauder and Shiseido.

SUNMI CHEW

Sr. Director of Clinical Education and Training

With over 20 years in the medical device industry, Sunmi developed a series of successful education programs, most recently at miraDry. Her passion is training and education for customers domestically and internationally.

Board of Directors

• David A. Present, MD, Chairman Founder and General Partner, Pansend Life Sciences, LLC
• Cherine Eldumiati Plumaker, Vice Chairman Founder and General Partner, Pansend Life Sciences, LLC
• Yuhang Zhao, PHD, MBA, Head of Global Development, Huadong Medicine Co., Ltd.
• Irina Erenburg, PHD, Chief Executive Officer, Blossom Innovations, LLC
• Seth Orlow, MD, PHD, Professor and Chair of Dermatology, NYU School of Medicine
• Tim Holt, MBA, Chief Executive Officer, R2 Technologies, Inc.

Partners

Huadong Medicine Company Limited, China

“We are delighted to have found a superb strategic partner in Huadong and particularly excited to work with their entire team to enter the Asia-Pacific Region, the most robust market in the world for our portfolio of cold-based treatments for both aesthetically lightening the normal pigmentation of the skin and the reduction and elimination of hyperpigmentation of specific problem areas of the skin due to aging, sun damage, and/or genetics.”

June 13, 2019 08:30 ET | Source: HC2 Holdings, Inc.

Press Release

Our Story

In 2014, R2 secured the exclusive license from Blossom Innovations & Massachusetts General Hospital to develop a technology based on their patented method of pausing melanin production. Since that time, R2 has conducted the design, development and extensive clinical research necessary to bring our first product to market in 2020.

2014
The Founding of R2
MGH & Blossom Innovations licensed exclusive intellectual property to R2 Technologies in San Ramon, CA. and starts to study the effect of cold on melanocytes when applied topically.
2015
Research
R2 begins the research and development of the technology around Cryomelanomodulation.

2015
2016
FDA Clearance
R2 receives clearance for the removal of benign lesions of the skin.
2017
FDA Clearance
R2 receives clearance for their next-generation system.

2017
2018
First Published Manuscript from founders
Lasers in Surgery and Medicine introduces the treatment of benign lesions utilizing a novel dermal cooling system.
2019
Strategic Partnership
R2 closes strategic investment and commercial partnership with Huadong Medicine Co., Ltd.

2019
2020
Unveiling
Technology will first be shown at ASLMS 2020

Fraxel is a registered trademark of Solta and CoolSculpting is a registered trademark of Allergan.

Stay in The Know

Home Team Science Events Contact

R2 Technologies is an Equal Opportunity Employer